Speakers

Expand/Collapse

Michael Fossel
President & Founder
Telocyte

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

10:05 am | Challenging Differentiated Approach to Neurodegeneration: A Unified Systems Model for Age-Related Neurodegenerative Disease

Andreas Jeromin
Chief Scientific Officer
Cohen Veterans Bioscience

Day Two

Thursday, August 26 2021

9:00 am | Blood-based biomarkers in AD : When the Future Becomes the Present

Chris Whelan
Associate Director & Head of Translational Genetics
Biogen

Day One

Wednesday, August 25 2021

2:40 pm | Chair Led Q&A

12:40 pm | Dementia, Biomarkers and Biobanks: Applying Proteomics at Population Scale

Leslie Holsinger
Executive Vice President of Research & Development
Cortexyme

Day One

Wednesday, August 25 2021

2:40 pm | Chair Led Q&A

2:00 pm | Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial; An Ongoing Phase 2/3 Clinical Trial Assessing the Activity of Atuzaginstat in Patients with Mild to Moderate Alzheimer’s Disease

Michela Gallagher
Founder & Chief Executive Officer
AgeneBio

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

9:30 am | Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial

Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio

Day One

Wednesday, August 25 2021

10:25 am | Chair Led Q&A

9:30 am | Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial

CJ Barnum
Head of Neuroscience
INmune Bio

Day Two

Thursday, August 26 2021

2:40 pm | Chair Led Q&A; Precision Through Combination Biomarkers

2:00 pm | What it Means to Demonstrate Target Engagement in Therapies that Target the Immune System: Role of Combination of Biomarkers.

12:20 pm | Chair Led Q&A; Presenting Biomarker Efficacy & Advances in Clinical Validation of Biomarker’s for Alzheimer’s Disease

11:00 am | Biomarkers to Evaluate Therapies that Target the Immune System in Early-Stage Alzheimer’s Trials: Patient Selection, Target Engagement, & Promising Technologies

Hans Moebius
Chief Medical Officer
Athira Pharma

Day One

Wednesday, August 25 2021

4:20 pm | Chair Led Q&A

4:00 pm | Advances in Direct, Functional, Non-Invasive Biomarkers; Athira’s Utilization of ERP P300

Juli Jones
Director & Head of Disease Biology
Cyclerion Therapeutics

Christopher Winrow
Head of Translational Medicine
Cyclerion Therapeutics

Day Two

Thursday, August 26 2021

3:20 pm | Chair Led Q&A; Translating Biomarkers from Preclinical to Clinical Development

3:00 pm | Leading the Vanguard - Early Clinical Assessment of Biomarkers to Drive Development of Alzheimer’s Disease Therapies

Michele Vendruscolo
Chief Scientific Officer
Wren Therapeutics

Day One

Wednesday, August 25 2021

4:20 pm | Chair Led Q&A

3:40 pm | Detection & Quantification of Amyloid Beta Oligomers

Jonathan Levenson
Vice President of Translational Biology
Tiaki Therapeutics

Day One

Wednesday, August 25 2021

4:20 pm | Chair Led Q&A

3:00 pm | Using Multi-Omics Data to Identify Novel Biomarkers & Biomarker Strategies

Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics

Day Two

Thursday, August 26 2021

10:05 am | Panel Discussion: Advances in Identifying Novel Non-Invasive Biomarkers to Identify Patients with Alzheimer’s Disease, Their Specific Subtype & Disease Progression

Felix Yeh
Head of Biomarkers
Alector

Day One

Wednesday, August 25 2021

2:40 pm | Chair Led Q&A

2:20 pm | Biomarker Strategies to Enable Successful Development of Immuno-Neurology Targets

Mark Frasier
Co-Chief Scientific Officer
The Michael J Fox Foundation

Day Two

Thursday, August 26 2021

10:05 am | Panel Discussion: Advances in Identifying Novel Non-Invasive Biomarkers to Identify Patients with Alzheimer’s Disease, Their Specific Subtype & Disease Progression

Nicole Bjorklund
Assistant Director – Scientific Affairs
Alzheimer’s Drug Discover Foundation

Day Two

Thursday, August 26 2021

2:40 pm | Chair Led Q&A; Precision Through Combination Biomarkers

2:30 pm | Emerging Biomarker Combinations for Personalized Alzheimer’s Disease Diagnosis & Treatment

Douglas Galasko
Associate Director
UCSD Shiley-Marcos Alzheimer’s Disease Research Center

Day Two

Thursday, August 26 2021

12:20 pm | Chair Led Q&A; Presenting Biomarker Efficacy & Advances in Clinical Validation of Biomarker’s for Alzheimer’s Disease

11:40 am | Presenter Led Audience Discussion

11:20 am | Mapping Alzheimer Biomarkers for Context of Use With the FDA BEST (Biomarkers, Endpoints, and other Tools) Guidance

Tom Megerian
Chief Medical Officer
Cognito Therapeutics

Day One

Wednesday, August 25 2021

11:40 am | Panel Discussion: Paradigm Shifting Digital Therapeutics to Treat Alzheimer’s Disease; Utilizing Digital Tools for Disease Modification

Brent Vaughan
Chief Executive Officer
Cognito Therapeutics

Day One

Wednesday, August 25 2021

11:40 am | Panel Discussion: Paradigm Shifting Digital Therapeutics to Treat Alzheimer’s Disease; Utilizing Digital Tools for Disease Modification

Stefan Barghorn
Senior Principal Research Scientist Molecular & Imaging Biomarkers
AbbVie

Day Two

Thursday, August 26 2021

9:25 am | Performance Data on Blood Based Biomarkers for Alzheimer’s Disease

Elizabeth Somers
Director of Diagnostic Development & Translational Medicine Diagnostic Development, Translational Medicine & Diagnostics
Eisai

Maria Maccecchini
Founder, President, CEO and Executive Board Member
Annovis Bio

Day Two

Thursday, August 26 2021

1:40 pm | Presentation details to be confirmed

2:40 pm | Chair Led Q&A; Precision Through Combination Biomarkers